Circulating microRNAs: Macro-utility as markers of prostate cancer?

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages

  Selth, Luke A ^a   Tilley, Wayne D ^a   Butler, Lisa M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; MICRORNA; MICRORNA 141; MICRORNA 195; MICRORNA 21; MICRORNA 221; MICRORNA 26A; MICRORNA 298; MICRORNA 346; MICRORNA 375; UNCLASSIFIED DRUG;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DIAGNOSTIC VALUE; DISEASE MARKER; GENE EXPRESSION; HUMAN; PREDICTION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

CARCINOMA; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864400776     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0010     Document Type: Review

References (109)

1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ et al. 2009 Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine 360 1310-1319. (doi:10.1056/NEJMoa0810696)
2. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova- Agadjanyan EL, Stirewalt DL et al. 2011 Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. PNAS 108 5003-5008. (doi:10.1073/pnas.1019055108)
3. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE & Hoon DS 2011 Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical Chemistry 57 84-91. (doi:10.1373/clinchem.2010.151845)
4. Attard G & de Bono JS 2011 Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clinical Cancer Research 17 3867-3875. (doi:10.1158/1078-0432.CCR-11-0943)
5. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV & Hannon GJ 2003 Dicer is essential for mouse development. Nature Genetics 35 215-217. (doi:10.1038/ng1253)
6. Blitzblau RC & Weidhaas JB 2010 MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Molecular Diagnosis & Therapy 14 335-342. (doi:10.2165/11587600-000000000-00000)
7. Boyerinas B, Park SM, Hau A, Murmann AE & Peter ME 2010 The role of let-7 in cell differentiation and cancer. Endocrine-Related Cancer 17 F19-F36. (doi:10.1677/ ERC-09-0184)
8. Bracken CP, Gregory PA, Khew-Goodall Y & Goodall GJ 2009 The role of microRNAs in metastasis and epithelial- mesenchymal transition. Cellular and Molecular Life Sciences 66 1682-1699. (doi:10.1007/s00018-009-8750-1)
9. Brase JC, Wuttig D, Kuner R & Sultmann H 2010 Serum microRNAs as non-invasive biomarkers for cancer. Molecular Cancer 9 306. (doi:10.1186/1476- 4598-9-306)
10. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R & Sultmann H 2011 Circulating miRNAs are correlated with tumor progression in prostate cancer. International Journal of Cancer 128 608-616. (doi:10.1002/ijc.25376)
11. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T & Hamdy FC 2012 Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer 106 768-774. (doi:10.1038/bjc.2011.595)
12. Bushati N & Cohen SM 2007 microRNA functions. Annual Review of Cell and Developmental Biology 23 175-205. (doi:10.1146/annurev.cellbio.23.090506. 123406)
13. Cacchiarelli D, Legnini I, Martone J, Cazzella V, D'Amico A, Bertini E & Bozzoni I 2011 miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine 3 258-265. (doi:10.1002/emmm.201100133)
14. Calin GA & Croce CM 2006 MicroRNA signatures in human cancers. Nature Reviews. Cancer 6 857-866. (doi:10.1038/nrc1997)
15. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M et al. 2004 Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS 101 2999-3004. (doi:10.1073/pnas. 0307323101)
16. Carlsbecker A, Lee JY, Roberts CJ, Dettmer J, Lehesranta S, Zhou J, Lindgren O, Moreno-Risueno MA, Vaten A, Thitamadee S et al. 2010 Cell signalling by micro-RNA165/6 directs gene dose-dependent root cell fate. Nature 465 316-321. (doi:10.1038/nature08977)
17. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X et al. 2008 Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 18 997-1006. (doi:10.1038/cr.2008.282)
18. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR & Zhang W 2011 Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6 e17745. (doi:10.1371/journal.pone.0017745)
19. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW & Lo YM 2008 Detection and characterization of placental microRNAs in maternal plasma. Clinical Chemistry 54 482-490. (doi:10.1373/clinchem.2007.097972)
20. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA et al. 2008 A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Research 68 8535-8540. (doi:10.1158/0008-5472.CAN-08-2129)
21. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T et al. 2008 Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncology 9 730-756. (doi:10.1016/S1470-2045(08)70179-7)
22. Coppola V, De Maria R & Bonci D 2009 MicroRNAs and prostate cancer. Endocrine-Related Cancer 17 F1-F17. (doi:10.1677/ERC-09-0172)
23. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK & Calin GA 2011 MicroRNAs in body fluids - the mix of hormones and biomarkers. Nature Reviews. Clinical Oncology 8 467-477. (doi:10.1038/nrclinonc.2011.76)
24. Croce CM 2009 Causes and consequences of microRNA dysregulation in cancer. Nature Reviews. Genetics 10 704-714. (doi:10.1038/nrg2634)
25. Djuranovic S, Nahvi A & Green R 2011 A parsimonious model for gene regulation by miRNAs. Science 331 550-553. (doi:10.1126/science.1191138)
26. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E & de Koning H 2009 Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. Journal of the National Cancer Institute 101 374-383. (doi:10.1093/ jnci/djp001)
27. Duttagupta R, Jiang R, Gollub J, Getts RC & Jones KW 2011 Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS ONE 6 e20769. (doi:10.1371/journal.pone.0020769)
28. Friedman RC, Farh KK, Burge CB & Bartel DP 2009 Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19 92-105. (doi:10.1101/gr.082701.108)
29. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N et al. 2008 Serum microRNAs are promising novel biomarkers. PLoS ONE 3 e3148. (doi:10.1371/journal.pone.0003148)
30. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ & Ward DC 2011 Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clinical Genitourinary Cancer 9 39-45. (doi:10.1016/j.clgc.2011.05.008)
31. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K & Carroll PR 2004 Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). Journal of Urology 171 2255-2259. (doi:10.1097/01.ju.0000127733.01845.57)
32. Grubb RL III, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D et al. 2008 Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU International 102 1524-1530. (doi:10.1111/j.1464-410X.2008.08214.x)
33. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM & Sczakiel G 2009 A robust methodology to study urine microRNA as tumor marker: microRNA- 126 and microRNA-182 are related to urinary bladder cancer. Urologic Oncology 28 655-661. (doi:10.1016/j. urolonc.2009.01.027)
34. Hanson EK, Lubenow H & Ballantyne J 2009 Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Analytical Biochemistry 387 303-314. (doi:10.1016/j.ab.2009.01.037)
35. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er. 2002-0032)
36. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA & Schalken JA 2003 DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. European Urology 44 8-15 (discussion 15-16). (doi:10.1016/ S0302-2838(03)00201-X)
37. Huang Z, Huang D, Ni S, Peng Z, Sheng W & Du X 2010 Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer 127 118-126. (doi:10.1002/ijc.25007)
38. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N & Reid G 2011 Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 6 e24145. (doi:10.1371/journal.pone. 0024145)
39. Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y et al. 2011 Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Digestive Diseases and Sciences 56 602-609. (doi:10.1007/s10620-010-1285-3)
40. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y & Ochiya T 2010 Secretory mechanisms and intercellular transfer of microRNAs in living cells. Journal of Biological Chemistry 285 17442-17452. (doi:10.1074/ jbc.M110.107821)
41. Koturbash I, Zemp FJ, Pogribny I&Kovalchuk O 2010 Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutation Research 722 94-105. (doi:10.1016/j.mrgentox.2010.05.006)
42. Kozomara A & Griffiths-Jones S 2010 miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Research 39 D152-D157. (doi:10.1093/nar/ gkq1027)
43. Kroh EM, Parkin RK, Mitchell PS & Tewari M 2010 Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50 298-301. (doi:10.1016/j.ymeth. 2010.01.032)
44. Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, Pisano M, Omenn GS & Hanash SM 2007 Discovery of cancer biomarkers through the use of mouse models. Cancer Letters 249 40-48. (doi:10.1016/j.canlet. 2006.12.032)
45. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, KinoshitaM, Watanabe S, Baba O, Kojima Y, Shizuta S et al. 2011 Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation. Cardiovascular Genetics 4 446-454. (doi:10.1161/ CIRCGENETICS.110. 958975)
46. LaConti JJ, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT & Wellstein A 2011 Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS ONE 6 e20687. (doi:10.1371/journal.pone. 0020687)
47. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M et al. 2007 A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129 1401-1414. (doi:10.1016/j.cell.2007.04.040)
48. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS et al. 2008 Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology 141 672-675. (doi:10.1111/j.1365-2141. 2008.07077.x)
49. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ & Schmittgen TD 2007 Expression profiling identifies microRNA signature in pancreatic cancer. International Journal of Cancer 120 1046-1054. (doi:10.1002/ijc.22394)
50. Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D & Wang K 2010 Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16 2170-2180. (doi:10.1261/rna.2225110)
51. Li J, Wang Y, Yu W, Chen J & Luo J 2011 Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochemical and Biophysical Research Communications 406 70-73. (doi:10.1016/j. bbrc.2011.01.111)
52. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R et al. 2010 A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. European Journal of Cancer 47 784-791. (doi:10.1016/j.ejca.2010.10. 025)
53. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH & Zhang YK 2011 High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Medical Oncology 19 618-626. (doi:10.1007/s12032-011-9923-y)
54. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A & Anderson B 2009 Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 4 e6229. (doi:10.1371/journal.pone.0006229)
55. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al. 2005 MicroRNA expression profiles classify human cancers. Nature 435 834-838. (doi:10.1038/nature03702)
56. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr & Thompson IM 2008 Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prevention Research 1 167-173. (doi:10.1158/1940- 6207.CAPR-08-0078)
57. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC & Ellinger J 2011 Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77 1265.e9-1265.e16. (doi:10.1016/j.urology.2011.01.020)
58. McDonald JS, Milosevic D, Reddi HV, Grebe SK & Algeciras-Schimnich A 2011 Analysis of circulating microRNA: preanalytical and analytical challenges. Clinical Chemistry 57 833-840. (doi:10.1373/clinchem. 2010.157198)
59. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST & Patel T 2007 MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133 647-658. (doi:10.1053/j. gastro.2007.05.022)
60. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al. 2008 Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105 10513-10518. (doi:10.1073/pnas.0804549105)
61. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, Sekiguchi M, Takeda S & Hashido K 2011 Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS ONE 6 e18388. (doi:10.1371/journal.pone.0018388)
62. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P & Blelloch R 2011 Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Research 71 550-560. (doi:10.1158/0008-5472.CAN-10- 1229)
63. Narayanan R, Jiang J, Gusev Y, Jones A, Kearbey JD, Miller DD, Schmittgen TD & Dalton JT 2010 MicroRNAs are mediators of androgen action in prostate and muscle. PLoS ONE 5 e13637. (doi:10.1371/journal.pone. 0013637)
64. Nauseef JT & Henry MD 2011 Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nature Reviews. Urology 8 428-439. (doi:10.1038/nrurol. 2011.85)
65. Pan X, Wang ZX & Wang R 2011 MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biology & Therapy 10 1224-1232. (doi:10.4161/cbt.10. 12.14252)
66. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E & Wong DT 2009 Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clinical Cancer Research 15 5473-5477. (doi:10.1158/1078-0432.CCR-09-0736)
67. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ & Schmittgen TD 2011 miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochemical and Biophysical Research Communications 406 518-523. (doi:10.1016/j.bbrc.2011. 02.065)
68. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Wurdinger T & Middeldorp JM 2010 Functional delivery of viral miRNAs via exosomes. PNAS 107 6328-6333. (doi:10.1073/pnas. 0914843107)
69. Peter ME 2009 Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8 843-852. (doi:10.4161/cc.8.6.7907)
70. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML & Duelli DM 2010 Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 5 e13515. (doi:10. 1371/journal.pone.0013515)
71. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y & Lin TY 2010 Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. Journal of Gastroenterology and Hepatology 25 1674-1680. (doi:10.1111/j. 1440-1746.2010.06417.x)
72. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R et al. 2009 miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research 69 7165-7169. (doi:10.1158/0008-5472.CAN-09-1448)
73. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A et al. 2008 MicroRNAs accurately identify cancer tissue origin. Nature Biotechnology 26 462-469. (doi:10.1038/nbt1392)
74. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, Benjamin H, Tamir R, Ezagouri M, Goren E et al. 2010 Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Modern Pathology 23 814-823. (doi:10.1038/modpathol.2010.57)
75. Roth C, Rack B, Muller V, Janni W, Pantel K & Schwarzenbach H 2010 Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research 12 R90. (doi:10.1186/bcr2766)
76. Ryan BM, Robles AI & Harris CC 2010 Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews. Cancer 10 389-402. (doi:10.1038/nrc2867)
77. Schaefer A, Stephan C, Busch J, Yousef GM & Jung K 2010 Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nature Reviews. Urology 7 286-297. (doi:10.1038/nrurol.2010.45)
78. Scher HI, Buchanan G, Gerald W, Butler LM & Tilley WD 2004 Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine- Related Cancer 11 459-476. (doi:10.1677/erc.1.00525)
79. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M et al. 2009 Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine 360 1320-1328. (doi:10.1056/ NEJMoa0810084)
80. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD & Butler LM 2011 Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer 131 652-661. (doi:10.1002/ijc.26405)
81. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ & deVere White RW 2007 An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. PNAS 104 19983-19988. (doi:10.1073/pnas. 0706641104)
82. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM & Breakefield XO 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology 10 1470-1476. (doi:10.1038/ncb1800)
83. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM et al. 2011 Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54 1767-1776. (doi:10.1002/hep.24538)
84. Steuber T, O'Brien MF & Lilja H 2008 Serum markers for prostate cancer: a rational approach to the literature. European Urology 54 31-40. (doi:10.1016/j.eururo.2008. 01.034)
85. Sun T, Wang Q, Balk S, Brown M, Lee GS & Kantoff P 2009 The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Research 69 3356-3363. (doi:10.1158/0008-5472.CAN- 08-4112)
86. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J et al. 2008 Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical Chemistry 54 1716-1724. (doi:10.1373/clinchem.2008.109603)
87. Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL & Andruss BF 2011 Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics 11 249-257. (doi:10.1586/erm.11.10)
88. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr R, Hartmann A et al. 2010 The microRNA profile of prostate carcinoma obtained by deep sequencing. Molecular Cancer Research 8 529-538. (doi:10.1158/1541-7786.MCR-09-0443)
89. Szczyrba J, Nolte E, Wach S, Kremmer E, Stohr R, Hartmann A, Wieland W, Wullich B & Grasser FA 2011 Downregulation of Sec23A protein by miRNA- 375 in prostate carcinoma. Molecular Cancer Research 9 791-800. (doi:10.1158/1541- 7786.MCR-10-0573)
90. Tam W 2008 The emergent role of microRNAs in molecular diagnostics of cancer. Journal of Molecular Diagnostics 10 411-414. (doi:10.2353/jmoldx.2008. 080067)
91. Taylor DD & Gercel-Taylor C 2008 MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology 110 13-21. (doi:10.1016/j.ygyno.2008.04.033)
92. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al. 2010 Integrative genomic profiling of human prostate cancer. Cancer Cell 18 11-22. (doi:10.1016/j.ccr.2010. 05.026)
93. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED et al. 2004 Prevalence of prostate cancer among men with a prostate-specific antigen level < or Z4.0 ng per milliliter. New England Journal of Medicine 350 2239-2246. (doi:10.1056/ NEJMoa031918)
94. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton- Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A et al. 2011 Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Science Translational Medicine 3 94ra72. (doi:10.1126/scitranslmed.3001970)
95. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ & Lotvall JO 2007 Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 9 654-659. (doi:10.1038/ncb1596)
96. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD & Remaley AT 2011 MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biology 13 423-433. (doi:10.1038/ ncb2210)
97. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G & Visakorpi T 2010 Androgen regulation of micro-RNAs in prostate cancer. Prostate 71 604-614. (doi:10.1002/ pros.21276)
98. Wang K, Zhang S, Weber J, Baxter D & Galas DJ 2010 Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research 38 7248-7259. (doi:10.1093/nar/gkq601)
99. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ & Wang K 2010 The microRNA spectrum in 12 body fluids. Clinical Chemistry 56 1733-1741. (doi:10.1373/clinchem.2010.147405)
100. Wienholds E, Koudijs MJ, van Eeden FJ, Cuppen E & Plasterk RH 2003 The microRNA-producing enzyme Dicer1 is essential for zebrafish development. Nature Genetics 35 217-218. (doi:10.1038/ng1251)
101. Winter J & Diederichs S 2011 MicroRNA biogenesis and cancer. Methods in Molecular Biology 676 3-22. (doi:10.1007/978-1-60761-863-8-1)
102. Winter J, Jung S, Keller S, Gregory RI & Diederichs S 2009 Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature Cell Biology 11 228-234. (doi:10.1038/ncb0309-228)
103. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K & Ju J 2007 Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13 1668-1674. (doi:10.1261/rna.642907)
104. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N & Gezer U 2011 Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biology 32 583-588. (doi:10.1007/s13277-011-0154-9)
105. Yuan A, Farber EL, Rapoport AL, Tejada D, Deniskin R, Akhmedov NB & Farber DB 2009 Transfer of micro- RNAs by embryonic stem cell microvesicles. PLoS ONE 4 e4722. (doi:10.1371/journal.pone.0004722)
106. Zen K & Zhang CY 2010 Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Medicinal Research Reviews 32 326-348. (doi:10.1002/med.20215)
107. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E et al. 2009 Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Science Signaling 2 ra81. (doi:10.1126/ scisignal.2000610)
108. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH & Ye DW 2010a Serum miRNA-21: elevated levels in patients with metastatic hormonerefractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71 326-331. (doi:10.1002/pros.21246)
109. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X et al. 2010b Secreted monocytic miR-150 enhances targeted endothelial cell migration. Molecular Cell 39 133-144. (doi:10.1016/j.molcel.2010.06.010)